Most Alzheimer’s research focuses on the sticky protein plaques that build up in the brain. A new laboratory study points to another problem that may matter just as much, however. The brain may lose part of its ability to take out the trash.
Researchers found that a copper-based drug helped restore a waste-clearing system at the blood-brain barrier, reduced toxic amyloid beta by 42%, and improved spatial learning by nearly 44% after 56 days in an Alzheimer’s mouse model.
It is not a cure, and it has not yet been shown to work in people with Alzheimer’s. Still, the findings offer a fresh route for a disease that keeps stealing memory, independence, and ordinary family moments.
A clogged drain in the brain
Alzheimer’s disease is linked to the buildup of amyloid beta, a protein that can collect into harmful plaques. In a healthy brain, some of that waste is moved out through the blood-brain barrier, the protective border that controls what can pass between the blood and the brain.
That barrier is not just a wall. It also has tiny transport systems, including P-glycoprotein pumps, that help push unwanted material out. When those pumps weaken, the brain’s cleanup crew may slow down, a bit like a sink drain that still exists but no longer clears water fast enough.
What the copper drug did
The new work was led by Dr. Jae Pyun at the Monash Institute of Pharmaceutical Sciences, with senior author Professor Joseph Nicolazzo and collaborators from the University of Melbourne. Their team tested a copper compound known as CuATSM in laboratory experiments using an Alzheimer’s mouse model.
The result was striking. The treatment increased the amount of P-glycoprotein clearance pumps by 24.1%, while toxic amyloid beta fell by 42%. The mice also performed better on spatial learning tasks, which test how well an animal remembers places and routes.
Dr. Pyun described the idea in plain language, saying the brain could “clear out the trapped waste.” Essentially, the treatment appeared to help the brain use its own cleaning system again, instead of only trying to attack plaques after they had already piled up.
Why this matters
Alzheimer’s is the most common form of dementia, and dementia is now one of the world’s biggest health challenges. The World Health Organization says 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases each year.
The pressure is also visible in national death records. In Australia, dementia including Alzheimer’s disease became the leading cause of death in 2024, overtaking ischemic heart disease, according to the Australian Bureau of Statistics.
That’s why even early laboratory findings can draw attention. Families do not experience Alzheimer’s as a chart or a technical diagnosis. They experience it in missed names, repeated questions, lost routines, and the quiet stress of watching someone familiar become harder to reach.
Not a cure yet
It is important to note that these results come from preclinical research, meaning they were seen before human Alzheimer’s trials. A mouse that remembers a route better is encouraging, but it is not the same thing as a person regaining memory.
Even so, CuATSM has one advantage over many early drug ideas. Professor Nicolazzo noted that the compound has already moved into clinical testing for conditions such as Parkinson’s disease and ALS, which may help researchers understand more about its safety profile.
On the other hand, Alzheimer’s drug development is full of hard lessons. The FDA has approved amyloid-targeting treatments such as Leqembi and Kisunla for certain people with early Alzheimer’s, but these medicines also come with careful eligibility rules and safety warnings. Progress is real, but it is not simple.
The next question
One mystery remains. The researchers still need to map exactly how the cleared amyloid leaves the brain after the blood-brain barrier starts working better. Science rarely moves in one clean line.
The team also suspects the drug may affect microglia, the brain’s immune cells. These cells can help chew up unwanted material, including amyloid plaques, but their role in Alzheimer’s is complicated and still being studied.
At the end of the day, what this study offers is not a miracle headline. It offers a possible new path, one focused on repairing the brain’s cleanup machinery before more damage builds up.
The official study has been published in ACS Chemical Neuroscience.
